Amgen Opens The Secret Curtain
Amgen Opens The Secret Curtain
“The biotech leader will host analysts and investors to drum up excitement for its pipeline — and its stock. Will it work? “
Amgen Opens The Secret Curtain
“The biotech leader will host analysts and investors to drum up excitement for its pipeline — and its stock. Will it work? “
Biotech uptick moves into March:
“February went out like a lion in biotechnology as filings for initial public offerings (IPOs) by three companies capped a flurry of activity in the sector. Acadia Pharmaceuticals, Alnylam Pharmaceuticals, and Ark Therapeutics announced filings in the wake of strong openings on Wall Street last month for GTx, Renovis, Corgentech, and DynaVax Technologies.”
And When ImClone’s Drug Doesn’t Work…
It’s not all roses for Erbitux: “The drug dramatically shrinks colon tumors in some patients. But in others, it has little effect — and no one knows why. “
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.

Recent Comments